1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > United States Market for Ankylosing Spondylitis Pharmacotherapy

This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.

Executive Summary
•The market for ankylosing spondylitis (AS) add-on pharmacotherapeutics currently comprises a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for TNF inhibitor refractory patients with moderate to severe disease represents a significant unmet need.
•Revenue generated from sales of TNF inhibitors for AS in the United States was approximately $x million in 2011 and was dominated by Abbott. Revenue for the AS therapeutic area is expected to increase to approximately $x million in 2017.
•Novel therapies aimed at alternative targets such as interleukin-17 (IL-17), interleukin 12/23 (IL-12/23), phosphodiesterase type 4 (PDE4), and janus kinase (JAK) are in active development, with an anti-IL-17 closest to approval for AS.
•Development of therapies for this complex disease is hindered by several factors, including incompletely understood pathogenesis of AS and a low level of disease awareness.
•Estimates of the prevalence of AS vary widely, but it occurs in approximately xx percent of the adult population. It usually presents in young adults, with a higher prevalence in males versus females.
•While many patients will respond well to non-steroidal anti-inflammatory drugs (NSAIDs), approximately .... percent (just under 200,000 in the United States in 2011) do not and are candidates for add-on therapy such as biologics.
•Diagnosis and initiation of appropriate treatment is often delayed by up to ten years due to unawareness of the disease.

Table Of Contents

United States Market for Ankylosing Spondylitis Pharmacotherapy
TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Total Ankylosing Spondylitis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 22
Forecasts and Trends 32
Demand Analysis 43
Market Share and Competitive Analysis 46
TNF Inhibitor Segment Breakdown 55
Non-TNF Biologics Segment Breakdown 66
The Last Word (Conclusions and Implications) 74
Appendix 79

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dyslipidaemia: KOL Insight

Dyslipidaemia: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have ...

COPD: KOL Insight

COPD: KOL Insight

  • $ 8 085
  • Industry report
  • April 2016
  • by Firstword Pharma

Is the COPD treatment market poised for a fundamental shift? After years of dominance by a handful of brands, change is in the air for COPD treatment. Will deep set preferences finally be overturned, ...

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

  • $ 6 995
  • Industry report
  • April 2016
  • by GBI Research

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia ...


ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.